Weight loss
Peptides for Weight Loss: What the GLP-1 Trials Show
Fat loss read from the primary literature — percentages, dropout rates and what happens after stopping.
11 matching articles
Compound
5 September 2026 · 10 min read
Semaglutide vs Tirzepatide: What the Head-to-Head Trial Evidence Actually Shows
Two approved incretin medicines, one direct comparison trial and a great deal of confusion in between. A source-checked reading of STEP 1, SURMOUNT-1, SURPASS-2 and the open-label SURMOUNT-5 comparison.
Semaglutide · Tirzepatide
31 August 2026 · 4 min read
Sleep Architecture as a Metabolic and Immunological Regulator: An Analytical Review
A critical analysis of how nocturnal sleep stages orchestrate systemic metabolic homeostasis, neuro-glymphatic clearance, and cell-mediated immune dynamics.
Growth hormone
31 August 2026 · 6 min read
Metabolic Approaches to Respiratory Health: Evaluating GLP-1 Agonism in Obstructive Sleep Apnea
Public discussions surrounding high-profile athletes like Shaquille O'Neal highlight an emerging clinical intersection: how GLP-1 receptor agonists influence obstructive sleep apnea through systemic metabolic remodeling.
Tirzepatide
31 August 2026 · 6 min read
Preserving Lean Mass During GLP-1 Receptor Agonist Protocols: Physiology and Nutritional Countermeasures
Rapid body weight reduction induced by GLP-1 receptor agonists presents a major clinical challenge: preventing disproportionate lean mass loss. We review the physiological mechanisms and dietary strategies required to preserve skeletal muscle integrity.
Semaglutide · Tirzepatide
31 August 2026 · 6 min read
Evaluating GLP-1 Receptor Agonism and Cancer Risk: Metabolic and Direct Molecular Pathways
An inquiry into how glucagon-like peptide-1 receptor agonists influence oncological outcomes, distinguishing indirect metabolic improvements from cell-signaling anti-tumor mechanisms.
31 August 2026 · 6 min read
Mitochondrial Signaling and Metabolic Homeostasis: An Editorial Review of MOTS-c
An analytical evaluation of MOTS-c, a mitochondrially derived peptide implicated in AMPK activation, cellular energy regulation, and systemic metabolic flexibility.
MOTS-c
31 August 2026 · 5 min read
Paradigm Shifts in Metabolic Pharmacotherapy: Deconstructing the GLP-1 Public Narrative
High-profile public discussions surrounding GLP-1 receptor agonists have reframed metabolic management from a narrative of willpower to one of central neuroendocrine regulation. We analyze the scientific mechanics behind this shift.
Semaglutide · Tirzepatide
31 August 2026 · 6 min read
Managing GLP-1 Discontinuation: Physiological Mechanisms and Post-Cessation Weight Rebound
An objective examination of neuroendocrine adaptations, resting metabolic rate alterations, lean mass retention, and strategy frameworks following GLP-1 receptor agonist cessation.
31 August 2026 · 14 min read
What Is Retatrutide? Mechanism, Phase 3 Results and Approval Status
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist at the GIP, GLP-1 and glucagon receptors. What the peer-reviewed trials show, how the 2026 topline Phase 3 results should be read, and why it is approved nowhere.
Semaglutide · Tirzepatide · Retatrutide
31 August 2026 · 6 min read
Selectivity in Growth Hormone Secretagogues: A Desk Review of Ipamorelin
An editorial examination of ipamorelin’s receptor selectivity, its historical development, and the current state of preclinical research regarding growth hormone axis modulation.
Ipamorelin · Hexarelin · Growth hormone
26 August 2026 · 8 min read
Reconstitution Math: From Vial Label to an Accurate Volume
Most dosing error in peptide work is arithmetic, not chemistry. How diluent volume, syringe units and net peptide content interact — and the three places the calculation usually breaks.
Retatrutide · BPC-157